ARCUTIS BIOTHERAPEUTICS, INC. Operating Income
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Operating Income of $16.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was $16.43M.
- ARCUTIS BIOTHERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$9.09M.
- ARCUTIS BIOTHERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was $18.39M.
- ARCUTIS BIOTHERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was $8.53M.
- ARCUTIS BIOTHERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$12.23M.
- ARCUTIS BIOTHERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$128.40M.
- ARCUTIS BIOTHERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$241.10M.
- ARCUTIS BIOTHERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$301.63M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.43M 10-Q · filed 2026-08-05 | $7.34M 10-Q · filed 2026-08-05 | $25.73M derived: sum of 3 quarters · filed 2026-08-05 | $34.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$9.09M 10-Q · filed 2026-05-06 | $9.30M derived: sum of 2 quarters · filed 2026-05-06 | $17.82M derived: sum of 3 quarters · filed 2026-05-06 | $3.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $18.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $26.91M derived: sum of 2 quarters · filed 2026-02-25 | $12.30M derived: sum of 3 quarters · filed 2026-08-05 | -$12.23M 10-K · filed 2026-02-25 |
| 2025-09-30 | $8.53M 10-Q · filed 2025-10-28 | -$6.08M derived: sum of 2 quarters · filed 2026-08-05 | -$30.61M 10-Q · filed 2025-10-28 | -$38.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$14.61M 10-Q · filed 2026-08-05 | -$39.14M 10-Q · filed 2026-08-05 | -$46.77M derived: sum of 3 quarters · filed 2026-08-05 | -$85.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$24.53M 10-Q · filed 2026-05-06 | -$32.16M derived: sum of 2 quarters · filed 2026-05-06 | -$71.23M derived: sum of 3 quarters · filed 2026-05-06 | -$121.30M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$46.70M derived: sum of 2 quarters · filed 2026-02-25 | -$96.78M derived: sum of 3 quarters · filed 2026-02-25 | -$128.40M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$39.07M 10-Q · filed 2025-10-28 | -$89.14M derived: sum of 2 quarters · filed 2025-10-28 | -$120.77M 10-Q · filed 2025-10-28 | -$181.93M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$50.08M 10-Q · filed 2025-08-06 | -$81.70M 10-Q · filed 2025-08-06 | -$142.87M derived: sum of 3 quarters · filed 2026-02-25 | -$179.77M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$31.62M 10-Q · filed 2025-05-06 | -$92.79M derived: sum of 2 quarters · filed 2026-02-25 | -$129.69M derived: sum of 3 quarters · filed 2026-02-25 | -$196.46M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$61.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$98.07M derived: sum of 2 quarters · filed 2026-02-25 | -$164.84M derived: sum of 3 quarters · filed 2026-02-25 | -$241.10M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$36.90M 10-Q · filed 2024-11-06 | -$103.67M derived: sum of 2 quarters · filed 2024-11-06 | -$179.93M 10-Q · filed 2024-11-06 | -$248.36M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$66.76M 10-Q · filed 2024-08-14 | -$143.03M 10-Q · filed 2024-08-14 | -$211.45M derived: sum of 3 quarters · filed 2025-02-25 | -$316.20M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$76.27M 10-Q · filed 2024-05-14 | -$144.69M derived: sum of 2 quarters · filed 2025-02-25 | -$249.44M derived: sum of 3 quarters · filed 2025-02-25 | -$315.26M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$68.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$173.17M derived: sum of 2 quarters · filed 2025-02-25 | -$239.00M derived: sum of 3 quarters · filed 2025-02-25 | -$301.63M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$104.75M 10-Q · filed 2023-11-03 | -$170.57M derived: sum of 2 quarters · filed 2023-11-03 | -$233.20M 10-Q · filed 2023-11-03 | -$304.49M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$65.83M 10-Q · filed 2023-08-08 | -$128.46M 10-Q · filed 2023-08-08 | -$199.74M derived: sum of 3 quarters · filed 2024-02-27 | -$256.82M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$62.63M 10-Q · filed 2023-05-09 | -$133.91M derived: sum of 2 quarters · filed 2024-02-27 | -$190.99M derived: sum of 3 quarters · filed 2024-02-27 | -$233.07M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$71.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$128.36M derived: sum of 2 quarters · filed 2024-02-27 | -$170.44M derived: sum of 3 quarters · filed 2024-02-27 | -$206.53M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$57.08M 10-Q · filed 2022-11-08 | -$99.16M derived: sum of 2 quarters · filed 2022-11-08 | -$135.24M 10-Q · filed 2022-11-08 | -$169.31M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$42.08M 10-Q · filed 2022-08-04 | -$78.17M 10-Q · filed 2022-08-04 | -$112.23M derived: sum of 3 quarters · filed 2023-02-28 | -$150.53M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$36.09M 10-Q · filed 2022-05-05 | -$70.15M derived: sum of 2 quarters · filed 2023-02-28 | -$108.45M derived: sum of 3 quarters · filed 2023-02-28 | -$144.08M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$34.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$72.37M derived: sum of 2 quarters · filed 2023-02-28 | -$107.99M derived: sum of 3 quarters · filed 2023-02-28 | -$136.65M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$38.30M 10-Q · filed 2021-11-04 | -$73.93M derived: sum of 2 quarters · filed 2021-11-04 | -$102.58M 10-Q · filed 2021-11-04 | -$115.58M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | -$35.63M 10-Q · filed 2021-08-05 | -$64.28M 10-Q · filed 2021-08-05 | -$77.27M derived: sum of 3 quarters · filed 2022-02-22 | -$91.92M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | -$28.65M 10-Q · filed 2021-05-06 | -$41.65M derived: sum of 2 quarters · filed 2022-02-22 | -$56.29M derived: sum of 3 quarters · filed 2022-02-22 | -$64.83M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | -$12.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | -$27.64M derived: sum of 2 quarters · filed 2022-02-22 | -$36.18M derived: sum of 3 quarters · filed 2022-02-22 | -$43.13M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$14.65M 10-Q · filed 2020-11-05 | -$23.19M derived: sum of 2 quarters · filed 2020-11-05 | -$30.14M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$8.54M 10-Q · filed 2020-08-11 | -$15.49M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$6.95M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | -$19.73M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |